Drug intelligence / Profile preview

cobra neurotoxin

Development stage
Preclinical
Modality
Native Peptides → Peptides, Recombinant Proteins and Enzymes
Administration
Injection, Topical
01

Overview

Cobra neurotoxin refers to a class of potent peptide toxins found in the venom of various cobra species (notably Naja naja and Naja atra). The most studied forms are short-chain and long-chain alpha-neurotoxins—three-finger toxins (3FTx)—that bind with high affinity to nicotinic acetylcholine receptors at the neuromuscular junction. This binding blocks synaptic transmission by preventing acetylcholine from activating its receptor, resulting in flaccid paralysis and potentially respiratory failure[1][3]. Some variants also modulate adenosine receptors in the central nervous system, producing both analgesic and hyperalgesic effects depending on dose[4]. Cobra neurotoxins have been investigated for their potential as painkillers and for treating conditions such as multiple sclerosis and rheumatoid arthritis[1][5][6]. They can be administered via injection or topical formulations. Their mechanism is distinct from beta-neurotoxins (which target voltage-gated sodium channels) but may overlap with other venom components like phospholipase A2.

Other names
alpha-cobrotoxinα-cobrotoxincobra short-chain neurotoxinNaja naja atra neurotoxinthree-finger toxin (3FTx) alpha-neurotoxin
02

Targets

ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)Muscle-type nicotinic acetylcholine receptorCHRNA7 (α7 nicotinic receptor)α9α10 nAChR (α9α10 nicotinic receptor)

Beyond the preview

Go deeper on cobra neurotoxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cobra neurotoxin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call